PillRx only · Capsule, Extended Release · Oral
Tolterodine
Tolterodine Tartrate
2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US5 NDCs
2 active makers
2 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 9 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$0.258
Latest avg · Jul 22, 2026
-18%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
12K
Rx · 2026 Q1
494K
Units dispensed
+8%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it2 active · 1 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Torrent Pharmaceuticals Limited | unknown | 8 | SUPPLYING |
| American Health Packaging | unknown | 2 | SUPPLYING |
| Major Pharmaceuticals | unknown | 1 | EXITED 2026 |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Mar 4, 2025RECALLRecall (Class III): Tolterodine Tartrate Extended-Release Capsules, 2 mg, 30 Capsules (3 x 10) Unit Dose carton, Rx only, Packaged and Dist…
Failed Dissolution Specifications: Out of specification results obtained during routine stability testing for dissolution. — Recalling firm: The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories — Nationwide in the USA